Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0LLHMK
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
CN105828840B ADC-139
|
|||||
| Synonyms |
CN105828840B ADC-139
Click to Show/Hide
|
|||||
| Organization |
Genentech Inc.
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 1 Indication(s)
Acute myeloid leukemia [ICD11:2A60]
Investigative
|
|||||
| Drug-to-Antibody Ratio |
1.57
|
|||||
| Antibody Name |
CN105828840B_ADC-139 antibody
|
|||||
| Antigen Name |
Myeloid cell surface antigen CD33 (CD33)
|
Antigen Info | ||||
| Payload Name |
Undisclosed
|
|||||
| Linker Name |
CN105828840B_ADC-139 linker
|
|||||
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≍ 100.00% (Day 14) | Positive CD33 expression (CD33+++/++) | ||
| Method Description |
All treatments were conducted at day 0 by a single dose, i.v, 0.5 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
|
||||
| In Vivo Model | HL-60 CDX model | ||||
| In Vitro Model | Adult acute myeloid leukemia | HL-60 cells | CVCL_0002 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≍ 100.00% (Day 14) | Positive CD33 expression (CD33+++/++) | ||
| Method Description |
All treatments were conducted at day 0 by a single dose, i.v, 1 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
|
||||
| In Vivo Model | HL-60 CDX model | ||||
| In Vitro Model | Adult acute myeloid leukemia | HL-60 cells | CVCL_0002 | ||
References
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.